How do hospital professionals involved in a randomised controlled trial perceive the value of genotyping vs. PCR-ribotyping for control of hospital acquired C. difficile infections?

Article English OPEN
Szczepura, Ala ; Manzoor, Susan ; Hardy, Katherine ; Stallard, Nigel ; Parsons, Helen ; Gossain, Savita ; Hawkey, Peter M (2014)
  • Publisher: Springer Nature
  • Journal: BMC Infectious Diseases, volume 14, pages 154-154 (eissn: 1471-2334)
  • Related identifiers: doi: 10.1186/1471-2334-14-154, pmc: PMC3997920
  • Subject: C. difficile tests | MLVA sub-typing | Value of test information | Research Article | Staff attitudes | Ribotyping | Infectious Diseases | Hospital infection control | RA

Background:\ud Despite scientific advances in typing of C. difficile strains very little is known about how hospital staff use typing results during periods of increased incidence (PIIs). This qualitative study, undertaken alongside a randomised controlled trial (RCT), explored this issue. The trial compared ribotyping versus more rapid genotyping (MLVA or multilocus variable repeat analysis) and found no significant difference in post 48 hour cases (C difficile transmissions).\ud \ud Methods:\ud In-depth qualitative interviews with senior staff in 11/16 hospital trusts in the trial (5 MLVA and 6 Ribotyping). Semi-structured interviews were conducted at end of the trial period. Transcripts were content analysed using framework analysis supported by NVivo-8 software. Common sub-themes were extracted by two researchers independently. These were compared and organised into over-arching categories or ‘super-ordinate themes’.\ud \ud Results:\ud The trial recorded that 45% of typing tests had some impact on infection control (IC) activities. Interviews indicated that tests had little impact on initial IC decisions. These were driven by hospital protocols and automatically triggered when a PII was identified. To influence decision-making, a laboratory turnaround time < 3 days (ideally 24 hours) was suggested; MLVA turnaround time was 5.3 days. Typing results were predominantly used to modify initiated IC activities such as ward cleaning, audits of practice or staff training; major decisions (e.g. ward closure) were unaffected. Organisational factors could limit utilisation of MLVA results. Results were twice as likely to be reported as ‘aiding management’ (indirect benefit) than impacting on IC activities (direct effect). Some interviewees considered test results provided reassurance about earlier IC decisions; others identified secondary benefits on organisational culture. An underlying benefit of improved discrimination provided by MLVA typing was the ability to explore epidemiology associated with CDI cases in a hospital more thoroughly.\ud \ud Conclusions:\ud Ribotyping and MLVA are both valued by users. MLVA had little additional direct impact on initial infection control decisions. This would require reduced turnaround time. The major impact is adjustments to earlier IC measures and retrospective reassurance. For this, turnaround time is less important than discriminatory power. The potential remains for wider use of genotyping to examine transmission routes.
  • References (40)
    40 references, page 1 of 4

    1. Panel TDRDEE, Banoo S, Bell D, Bossuyt P, Herring A, Mabey D, Poole F, Smith PG, Sriram N, Wongsrichanalai C, Linke R, O'Brien R, Perkins M: Evaluation of diagnostic tests for infectious diseases: general principles. Nat Rev Microbiol 2008, 6(11 Suppl):S16-26.

    2. Szczepura A, Kankaanpa\0308a J: Assessment of health care technologies: case studies, key concepts and strategic studies. Chichester: Wiley; 1996.

    3. Diagnostics Assessment Programme manual [http://www.nice.org.uk/ aboutnice/whatwedo/aboutdiagnosticsassessment/DiagnosticsAssessment ProgrammeManual.jsp]

    4. Testore GP, Pantosti A, Cerquetti M, Babudieri S, Panichi G, Gianfrilli PM: Evidence for cross-infection in an outbreak of Clostridium difficile-associated diarrhoea in a surgical unit. J Med Microbiol 1988, 26(2):125-128.

    5. Kamthan AG, Bruckner HW, Hirschman SZ, Agus SG: Clostridium difficile diarrhea induced by cancer chemotherapy. Arch Intern Med 1992, 152(8):1715-1717.

    6. Gerard M, Defresne N, Daneau D, Van der Auwera P, Delmee M, Bourguignon AM, Meunier F: Incidence and significance of Clostridium difficile in hospitalized cancer patients. Eur J Clin Microbiol Infect Dis 1988, 7(2):274-278.

    7. Cumming AD, Thomson BJ, Sharp J, Poxton IR, Fraser A: Diarrhoea due to Clostridium difficile associated with antibiotic treatment in patients receiving dialysis: the role of cross infection. Br Med J (Clin Res Ed) 1986, 292(6515):238-239.

    8. Kuijper EJ, Coignard B, Tull P: Emergence of Clostridium difficileassociated disease in North America and Europe. Clin Microbiol Infect 2006, 12(Suppl 6):2-18.

    9. Bartlett JG: Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002, 346(5):334-339.

    10. Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J Jr: Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995, 16(8):459-477.

  • Metrics
    No metrics available
Share - Bookmark